Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Opinion
Video

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Subscribe Now!
Recent Videos
At ARVO 2025, Christine Kay, MD, shares interim results from the PRISM trial population extension cohort
Related Content
An implantable solution fills the treatment gap for AMD patients

An implantable solution fills the treatment gap for AMD patients

Federico Badalà, MD
August 13th 2025
Article
Q&A: Jennifer I. Lim, MD, shares insights from the DAVIO-2 study

Q&A: Jennifer I. Lim, MD, shares insights from the DAVIO-2 study

Jennifer Lim, MD, FARVO, FASRS;Sydney M Crago;Martin David Harp
August 13th 2025
Article
CHMP issues positive opinion for Alteogen’s aflibercept biosimilar, EYLUXVI

CHMP issues positive opinion for Alteogen’s aflibercept biosimilar, EYLUXVI

Martin David Harp
August 13th 2025
Article
TEASE and SAGA study data to be presented by Alkeus Pharmaceuticals at ASRS 2025

TEASE and SAGA study data to be presented by Alkeus Pharmaceuticals at ASRS 2025

Sydney M Crago
August 13th 2025
Article
Scuba divers and surfers face dual light exposure that may accelerate AMD

Scuba divers and surfers face dual light exposure that may accelerate AMD

Lynda Charters
August 13th 2025
Article
Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy

Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy

Martin David Harp
August 13th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.